Small molecules as therapeutic drugs for Alzheimer's disease

Darryll M.A. Oliver, P (Hemachandra) Reddy

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (Aβ). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta-carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free-radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto-Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate Aβ induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss.

Original languageEnglish (US)
Pages (from-to)47-62
Number of pages16
JournalMolecular and Cellular Neuroscience
Volume96
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Alzheimer Disease
Antioxidants
Mitochondria
Aptitude
Pharmaceutical Preparations
Therapeutics
Poisons
Cholinesterase Inhibitors
beta Carotene
Mitochondrial Membranes
Blood-Brain Barrier
Mitochondrial DNA
Amyloid
Energy Metabolism
Ascorbic Acid
DNA Damage
Free Radicals
Glutathione
Neurotransmitter Agents
Cations

Keywords

  • Aging
  • Alzheimer's disease
  • Disease
  • Huntington's disease
  • Mitochondria-targeted molecules
  • Mitochondrial dysfunction
  • Mitophagy and mitochondrial dynamics
  • Oxidative stress
  • Parkinson

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Small molecules as therapeutic drugs for Alzheimer's disease. / Oliver, Darryll M.A.; Reddy, P (Hemachandra).

In: Molecular and Cellular Neuroscience, Vol. 96, 01.04.2019, p. 47-62.

Research output: Contribution to journalReview article

Oliver, Darryll M.A. ; Reddy, P (Hemachandra). / Small molecules as therapeutic drugs for Alzheimer's disease. In: Molecular and Cellular Neuroscience. 2019 ; Vol. 96. pp. 47-62.
@article{7c3b0652974b416781d7d54bb650232c,
title = "Small molecules as therapeutic drugs for Alzheimer's disease",
abstract = "Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (Aβ). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta-carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free-radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto-Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate Aβ induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss.",
keywords = "Aging, Alzheimer's disease, Disease, Huntington's disease, Mitochondria-targeted molecules, Mitochondrial dysfunction, Mitophagy and mitochondrial dynamics, Oxidative stress, Parkinson",
author = "Oliver, {Darryll M.A.} and Reddy, {P (Hemachandra)}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.mcn.2019.03.001",
language = "English (US)",
volume = "96",
pages = "47--62",
journal = "Molecular and Cellular Neuroscience",
issn = "1044-7431",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Small molecules as therapeutic drugs for Alzheimer's disease

AU - Oliver, Darryll M.A.

AU - Reddy, P (Hemachandra)

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (Aβ). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta-carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free-radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto-Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate Aβ induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss.

AB - Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (Aβ). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta-carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free-radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto-Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate Aβ induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss.

KW - Aging

KW - Alzheimer's disease

KW - Disease

KW - Huntington's disease

KW - Mitochondria-targeted molecules

KW - Mitochondrial dysfunction

KW - Mitophagy and mitochondrial dynamics

KW - Oxidative stress

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=85062960406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062960406&partnerID=8YFLogxK

U2 - 10.1016/j.mcn.2019.03.001

DO - 10.1016/j.mcn.2019.03.001

M3 - Review article

VL - 96

SP - 47

EP - 62

JO - Molecular and Cellular Neuroscience

JF - Molecular and Cellular Neuroscience

SN - 1044-7431

ER -